We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

62 hedge funds and large institutions have $226M invested in Foghorn Therapeutics in 2022 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

65,000% more call options, than puts

Call options by funds: $651K | Put options by funds: $1K

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

3% more funds holding

Funds holding: 60 → 62 (+2)

6% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 17

0.18% less ownership

Funds ownership: 63.36% → 63.18% (-0.18%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

37% less capital invested

Capital invested by funds: $357M → $226M (-$132M)

Holders
62
Holders Change
+2
Holders Change %
+3.33%
% of All Funds
1.07%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
8
Increased
18
Reduced
17
Closed
6
Calls
$651K
Puts
$1K
Net Calls
+$650K
Net Calls Change
+$648K

Top Buyers

1
RWM
Rockwood Wealth Management
Pennsylvania
+$1.6M
2
AQR Capital Management
AQR Capital Management
Connecticut
+$908K
3
Citadel Advisors
Citadel Advisors
Florida
+$871K
4
Victory Capital Management
Victory Capital Management
Texas
+$483K
5
TI
Trexquant Investment
Connecticut
+$286K

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$2.39M
2
DCM
Driehaus Capital Management
Illinois
-$681K
3
BlackRock
BlackRock
New York
-$341K
4
DTL
Dynamic Technology Lab
Singapore
-$279K
5
BC
Birchview Capital
Vermont
-$257K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$109M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$29.3M -$226K -17,546 -0.5%
AG
3
Artal Group
Luxembourg
$14.8M – – –
EC
4
Euclidean Capital
New York
$10.8M – – –
BlackRock
5
BlackRock
New York
$9.07M -$341K -26,496 -2%
Morgan Stanley
6
Morgan Stanley
New York
$8.89M -$2.39M -185,347 -15%
Vanguard Group
7
Vanguard Group
Pennsylvania
$8.69M +$68.6K +5,333 +0.5%
DM
8
Deerfield Management
New York
$6.67M – – –
AI
9
Alphabet Inc
California
$4.3M – – –
Point72 Asset Management
10
Point72 Asset Management
Connecticut
$3.33M +$162K +12,600 +3%
State Street
11
State Street
Massachusetts
$3.19M +$20.4K +1,586 +0.4%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.16M +$156K +12,120 +3%
DCM
13
Driehaus Capital Management
Illinois
$2.83M -$681K -52,889 -14%
BC
14
Birchview Capital
Vermont
$2.27M -$257K -20,000 -7%
Northern Trust
15
Northern Trust
Illinois
$1.58M -$36.7K -2,849 -2%
Millennium Management
16
Millennium Management
New York
$1.12M -$107K -8,312 -6%
RWM
17
Rockwood Wealth Management
Pennsylvania
$1.06M +$1.6M +124,030 New
AQR Capital Management
18
AQR Capital Management
Connecticut
$606K +$908K +70,587 New
Citadel Advisors
19
Citadel Advisors
Florida
$581K +$871K +67,692 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$569K +$196K +15,254 +30%
N
21
Nuveen
North Carolina
$490K -$32.8K -2,551 -4%
Charles Schwab
22
Charles Schwab
California
$456K -$309 -24 -0%
BBA
23
Baker Bros. Advisors
New York
$386K – – –
Victory Capital Management
24
Victory Capital Management
Texas
$322K +$483K +37,500 New
RJA
25
Raymond James & Associates
Florida
$250K +$12.9K +1,000 +4%
1
2 3

FHTX Hedge Fund Activity: Q3 2022 in Review

62 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q3 2022, worth a combined $226M — down 37% from $357M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new FHTX positions and 6 closed out — a net gain of 2 holders — while 18 added to existing stakes and 17 trimmed.

The largest buyer was Rockwood Wealth Management, opening a new position worth an estimated $1.6M. The largest seller was Morgan Stanley, cutting an estimated $2.39M.

  • 62 institutional investors held Foghorn Therapeutics (FHTX) as of Q3 2022, up from 60 in Q2 2022.
  • Funds reported $226M of Foghorn Therapeutics stock for Q3 2022, down 37% quarter-over-quarter.
  • 8 funds opened new Foghorn Therapeutics positions in Q3 2022 and 6 closed out, a net change of +2 holders.
  • The largest Foghorn Therapeutics buyer in Q3 2022 was Rockwood Wealth Management, an estimated $1.6M added.
  • The largest Foghorn Therapeutics seller in Q3 2022 was Morgan Stanley, an estimated $2.39M sold.

Based on aggregated 13F filings for Q3 2022.